KCI Corporate Profile
Overview
Kinetic Concepts, Inc. (NYSE: KCI) is a leading global medical technology company devoted to the discovery, development, manufacture and marketing of innovative, high-technology therapies and products for the wound care, regenerative medicine and therapeutic support system markets. KCI’s product portfolio offers healthcare professionals and their patients a proven clinical advantage in all care settings with therapies that improve patient outcomes while helping to reduce the overall cost of care. For more information, visit the company’s Web site at www.kci1.com
A History of Innovation
KCI was founded in 1976 by Dr. Jim Leininger who, as an accident and emergency physician, pioneered the use of “kinetic” or motion therapy to improve dramatically the survival rates for patients who are immobile due to critical injury. Today, KCI develops therapeutic support systems that address a full range of specialized patient needs including products for the wound care, bariatric and critical care markets. In 1996, KCI introduced an innovative approach to the treatment and management of serious, complex wounds through the use of sub-atmospheric or negative pressure. Known today in the UK as “topical negative pressure” therapy (TNP) and elsewhere as “negative pressure wound therapy” (NPWT) KCI’s proprietary Vacuum Assisted Closure®, or V.A.C.® Therapy System has changed the advanced wound care market and today remains the most clinically proven alternative for the treatment and management of complex, hard-to-heal wounds, ulcers, and partial thickness burns.
Research and Development (R&D)
KCI continues to invest in innovation with an ongoing commitment to research and development aimed at improving patient outcomes while reducing the overall cost of care. In 2010, KCI invested approximately $90 million in its R&D efforts, which are managed by approximately 150 clinical research and development professionals.
Clinical Studies
The KCI product portfolio has an unprecedented body of clinical evidence that demonstrates clinical efficacy and cost-effectiveness. The KCI V.A.C® Therapy System is the leader, with:
- 31 Randomised Clinical Trials
- More than 715 Peer Reviewed Studies
- More than 855 Abstracts
- 71 Medical Text Book Citations
Therapies
KCI products address a full range of patient needs and are used by healthcare professionals around the world in a wide range of care settings, including acute care hospitals, long-term care and skilled nursing facilities, home health agencies and wound care clinics throughout the world.
Negative Pressure Technology Platform — The KCI V.A.C.® Therapy System is the only TNP/NPWT indicated for promoting wound healing that include specific mechanisms of action such as preparing the wound bed for closure, reducing oedema, promoting granulation tissue formation and perfusion, and removing exudate and infectious material. KCI’s ActiV.A.C.® Therapy System, which is designed for ambulatory patients, remains the only NPWT alternative that is specifically cleared for home use.
Regenerative Medicine — KCI entered the fast-growing tissue regeneration market in 2008 with the acquisition of LifeCell Corporation, a leading provider of human and porcine- based tissue regeneration products. For more information visit www.lifecell.com
Therapeutic Support Systems — The KCI product portfolio includes a full range of specialty hospital beds, mattress replacement systems and overlays designed to address pulmonary complications associated with immobility, reduce skin breakdown, and assist carers in the safe and dignified handling of bariatric patients.
KCI at a Glance
| Worldwide Headquarters | San Antonio, Texas |
|---|---|
| President and CEO | Joseph F. Woody |
| Web Address | www.kci1.com |
| Stock Exchange | NYSE: KCI |
| Primary Business | Medical devices |
| Employees | ~7,000 |
| Operations | More than 20 countries |
| Manufacturing Locations | U.S. and Ireland |
| 2010 Annual Revenue | $2,002 million |
| 2010 Net Earnings | $256.1 million |
| 2010 Net Earnings Per Diluted Share | $3.57 |
| 2010 Research and Development Investment | $90.9 million |
Revenue by Region and Business ($M)
| North America | EMEA/APAC | Total | |
|---|---|---|---|
| Negative Pressure Technology Platform | $1,070 | $334.8 | $1,405 |
| Therapeutic Support Systems | $178 | $92.2 | $270 |
| Total | $1,248 | $427 | $1,675 |
Financial
- Original NASDAQ IPO in 1988
- Leveraged buy-out in 1997
- Second IPO in February 2004 on NYSE, resulting in one of largest medical technology IPOs in U.S. history
- KCI was added to Standard & Poor’s MidCap 400 Index in 2007
Global Presence
KCI does business in more than 20 countries in Europe, the Middle East and Africa (EMEA) and Asia Pacific regions. KCI’s worldwide headquarters is located in San Antonio, Texas. KCI’s EMEA Region office is located in Amsterdam, The Netherlands. KCI’s Asia Pacific Region has offices in Shanghai, Japan, China and Singapore.
Contact:
Kinetic Concepts, Inc.
Joe Izbrand
Office: 210-255-6251; Wireless: 210-867-9934
media@kci1.com
This Web page contains information about products which may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use.
Updated: 1 February 2012